- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Instagram Pages
Here you can access stories featured on our instagram page. Want more biosimilar news? Sign up for our weekly newsletter, delivered to your inbox every Wednesday here.
More Research Finds Low Awareness of Biosimilars Among Oncology Providers
NHS Provides Update on Biosimilar Adalimumab With a Focus on ISRs
ye on Pharma: Biocon Reports Its Highest-Ever Revenue and Profit Growth for Q3
eview Points to Nocebo Effect as a Cause of Higher Discontinuation Rates for Biosimilars
Coherus Settles With AbbVie, Sues Amgen, Over Biosimilar Adalimumab
ncreases in Insulin Prices Drove Spending Over 4 Years, Report Says
uropean Report Says M&As Affecting Biosimilars Need Scrutiny
Drugs Targeted by Biosimilars Are Responsible for Some of the Highest Hospital Spending
Sanctions Against Samsung BioLogics Suspended Pending Court Ruling
ales of Oncology Reference Products Far Outpace R&D Costs, Study Finds
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
